Skip to main content
. 2020 Jul 7;10(7):e038430. doi: 10.1136/bmjopen-2020-038430

Table 2.

Study schedule and assessments

Outcome measures Baseline assessment (consent to the study) Baseline
MRI scan
Treatment Monday–Friday for 4–6 weeks 8 weeks follow-up assessment 16 weeks follow-up assessment 16 weeks MRI scan 26 weeks follow-up
assessment
Visit window Within 14 days of Baseline Assessment +14 days of MRI Scan ±1 week from Randomisation ±1 week from Randomisation Within 14 days of 16 week Follow-up Assessment ±1 week from
randomisation
HDRS-17 ✓Only if baseline assessment exceeds 4 weeks
MGH ✓ Only if Baseline assessment exceeds 4 weeks
BDI-II
PHQ-9
WSAS
GAD7
EQ-5D-5L
THINC-it
SCID-5
CTQ
QIDS-SR
Client Resource Questionnaire
Patient Acceptability
Side effects checklist (adverse events)
fMRI
MRI
rsfMRI
MRS
Diffusion-weighted imaging

BDI-II, Beck Depression Inventory-II; CTQ, Childhood Trauma Questionnaire; EQ-5D-5L, EuroQoL-five-Dimensions-5-Level; GAD-7, Generalised Anxiety Disorder-7; HDRS-17, Hamilton Depression Rating Scale-17; MGH, Massachusetts General Hospital; MRS, MR spectroscopy; QIDS-SR, Quick Inventory of Depressive Symptomatology; rsfMRI, resting state functional MRI; SCID-5, Structured Clinical Interview-5; THINC-it, THINC-Integrated Tool; WSAS, Work and Social Adjustment Scale.